The next generation therapeutics market is estimated to grow from USD 0.1 billion in 2029 to USD 2.7 billion by 2035, at a CAGR of 63.1% during the forecast period, till 2035.
Global industry leaders are pushing the development of next-generation RNA therapies and vaccines to get over the aforementioned obstacles. Further, several companies also provide cutting-edge technological platforms for the creation, development, and production of innovative RNA therapies and vaccines.
Circular RNA (circRNA), endless RNA (eRNA), self-amplifying RNA (saRNA), and transfer RNA (tRNA) are examples of emerging modalities that exhibit improved structural stability, expression specificity, targeted delivery, and non-immunogenic characteristics. These characteristics allow their utilization across various therapeutic applications including breast cancer and influenza. Given the current trends and anticipated potential of the RNA therapies and vaccines industry, the market is expected to grow at a healthy CAGR in the near future.
This momentum is further reinforced by ongoing technological advancements, including the development of advanced lipid nanoparticle and exosome-based delivery systems that address prior challenges related to stability and targeted delivery. Additionally, innovations such as self-amplifying RNA platforms have enabled dose and cost optimization, while the integration of AI-driven tools has accelerated sequence design, optimization, and candidate selection timelines. Moreover, the increasing global burden of diseases including infectious diseases, cancer, and genetic disorders combined with supportive regulatory frameworks, such as fast-track designations for orphan drugs and a growing number of product approvals, continues to drive market demand. At the same time, a highly collaborative ecosystem involving biotechnology companies, contract development and manufacturing organizations (CDMOs), and research institutions is fostering innovation and investment in precision medicine approaches, enabling RNA-based therapies to selectively direct protein expression or silence disease-associated genes.
In addition, delivery hurdles persist as RNA molecules are fragile and prone to rapid degradation by RNases, while lipid carriers frequently struggle with inefficient endosomal escape, off-target effects, or immune activation that can diminish potency or raise toxicity concerns, particularly outside the liver. Logistical challenges stem from stringent ultra-cold storage and distribution requirements, which significantly limit reach in low-resource settings. These issues are further compounded by evolving regional regulatory frameworks, geopolitical risks associated with dual-use technologies, and persistent public hesitancy driven by misinformation, collectively extending timelines, increasing financial risks for smaller innovators, and underscoring the need for continued innovation to achieve mainstream viability.
The market for next-generation RNA treatments is segmented across various modalities, including vaccines and therapeutics. According to the next generation RNA therapeutics market forecast, the therapeutics sub-segment is expected to hold a larger proportion (>80%) in 2035. Furthermore, during the forecast period, this sub-segment is anticipated to increase at a notable rate. This is mainly because medicines have a wider range of possible applications than vaccinations. Therapeutics can treat both acute and chronic illnesses, increasing their market potential, in contrast to vaccines, which are mostly preventive and target infectious diseases.
Which molecule type exhibits the fastest growth in the next-generation RNA therapeutics sector?
According to the industry prediction, saRNA molecules are expected to have around 60% of the total market share by 2035. Additionally, the market is anticipated to see a significant rise in the proportion of saRNA molecules, expanding at a CAGR of 73.6% over the course of the projected period. This is because, in contrast to other RNA therapies like siRNAs, its double-stranded structure allows for enhanced gene expression at the transcriptional level. This guarantees the development of larger amounts of proteins that can be used to treat illnesses.
Which Target Indication Has the Biggest Market Share for RNA Therapeutics?
The advanced solid tumors subsegment is anticipated to hold the largest (~35%) market share in 2035, according to the next generation RNA therapies market analysis. This trend can be attributed to the rising global prevalence of oncological diseases, which continue to pose significant health challenges. Furthermore, the hereditary bone marrow failure syndrome sub-segment is anticipated to register a comparatively higher CAGR in the near term. This growth is driven by the rarity and predominantly monogenic nature of inherited bone marrow failure disorders, coupled with the current lack of effective therapeutic options.
Next Generation RNA Therapeutics Market: Growth and Trends
RNA-based treatments have become one of the most important therapeutic approaches in the contemporary healthcare sector over time. RNA therapeutics play a critical role in protein expression and the regulation of gene activity. Additionally, when compared to conventional treatment methods, they provide improved therapeutic and safety characteristics. The extremely unstable nature of these molecules and their distribution in sufficient concentrations, however, raise several issues.Global industry leaders are pushing the development of next-generation RNA therapies and vaccines to get over the aforementioned obstacles. Further, several companies also provide cutting-edge technological platforms for the creation, development, and production of innovative RNA therapies and vaccines.
Circular RNA (circRNA), endless RNA (eRNA), self-amplifying RNA (saRNA), and transfer RNA (tRNA) are examples of emerging modalities that exhibit improved structural stability, expression specificity, targeted delivery, and non-immunogenic characteristics. These characteristics allow their utilization across various therapeutic applications including breast cancer and influenza. Given the current trends and anticipated potential of the RNA therapies and vaccines industry, the market is expected to grow at a healthy CAGR in the near future.
Growth Drivers: Strategic Enablers of Market Expansion
The RNA therapeutics and RNA vaccines market is driven by a numerous factors underscoring its transformative impact on modern medicine and supporting its accelerated growth trajectory. A key growth driver has been the strong real-world validation of mRNA-based COVID-19 vaccines, which demonstrated the ability for rapid development, testing, and deployment while maintaining high efficacy against evolving pathogens. This success has significantly strengthened confidence in the platform, triggering substantial investments in the form of venture capital, strategic partnerships, and pipeline expansion across therapeutic areas such as oncology, rare genetic disorders, chronic diseases, and personalized vaccines.This momentum is further reinforced by ongoing technological advancements, including the development of advanced lipid nanoparticle and exosome-based delivery systems that address prior challenges related to stability and targeted delivery. Additionally, innovations such as self-amplifying RNA platforms have enabled dose and cost optimization, while the integration of AI-driven tools has accelerated sequence design, optimization, and candidate selection timelines. Moreover, the increasing global burden of diseases including infectious diseases, cancer, and genetic disorders combined with supportive regulatory frameworks, such as fast-track designations for orphan drugs and a growing number of product approvals, continues to drive market demand. At the same time, a highly collaborative ecosystem involving biotechnology companies, contract development and manufacturing organizations (CDMOs), and research institutions is fostering innovation and investment in precision medicine approaches, enabling RNA-based therapies to selectively direct protein expression or silence disease-associated genes.
Market Challenges: Critical Barriers Impeding Progress
Despite the abovementioned advantages, the RNA therapeutics and RNA vaccines market faces significant hurdles, that can slow the pace of transition and raise barriers for widespread implementation. Manufacturing remains exceptionally complex and capital-intensive, requiring specialized cleanroom facilities, rigorous quality oversight, and labor-intensive purification steps that significantly increase costs. These challenges also create bottlenecks in raw material supply and skilled personnel availability, often limiting production volumes and increasing vulnerability to recalls due to unexpected safety signals or inconsistencies.In addition, delivery hurdles persist as RNA molecules are fragile and prone to rapid degradation by RNases, while lipid carriers frequently struggle with inefficient endosomal escape, off-target effects, or immune activation that can diminish potency or raise toxicity concerns, particularly outside the liver. Logistical challenges stem from stringent ultra-cold storage and distribution requirements, which significantly limit reach in low-resource settings. These issues are further compounded by evolving regional regulatory frameworks, geopolitical risks associated with dual-use technologies, and persistent public hesitancy driven by misinformation, collectively extending timelines, increasing financial risks for smaller innovators, and underscoring the need for continued innovation to achieve mainstream viability.
Next Generation RNA Therapeutics Market: Key Insights
The report delves into the current state of the next generation therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:
- 73% of the next generation therapies being developed by various industry players are in discovery and preclinical stages; most of these therapies primarily focus on the treatment of infectious diseases.
- 80% of the clinical stage next generation therapies are in phase I and phase I / II; notably, around 60% clinical stage next generation therapies / vaccines are designed for intramuscular administration.
- Despite being in early stages of development, circular RNA therapies form a rapidly advancing therapy segment; this highly stable and efficient therapeutic modality is anticipated to gain significant popularity in the coming future.
- ~40% therapies are being evaluated in late-stages of development, highlighting the significant potential of next generation RNA technologies in therapy development.
- Majority of the clinical trials (21%) were registered in 2024; notably, most of the (~60%) clinical trials completed in the RNA therapeutics and vaccines domain were focused on infectious diseases.
- Recently, the exploration of RNA therapeutics and vaccines in targeting various disorders has gained momentum, consequently drawing attention from several industry players to conduct more trials in this domain.
- Around 30% of the patents related to RNA therapeutics and vaccines have been published in 2024, reflecting numerous advancements in the field of RNA-based therapies and technologies.
- 53% of the deals inked in this market are focused on clinical research of saRNA therapeutics / vaccines; of these, 50% partnerships focus on the evaluation of therapies targeting oncological disorders.
- Around 40% of the investments made in this domain were reported in the year 2021; notably venture capital emerged as the most prominent funding model, with Series A rounds accounting for 64% of transactions.
- In 2029, the market size is estimated to be around USD 0.1 billion; this value is further projected to reach about USD 2.7 billion in 2035, growing at an annualized CAGR of 63.1%, during the forecast period till 2035.
Next Generation RNA Therapeutics Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Modality
- Therapeutics
- Vaccines
Type of Molecule
- circRNA
- sacRNA
- saRNA
Target Indication
- Advanced Solid Tumors
- Hepatocellular Carcinoma
- Inherited Bone Marrow Failure Syndrome
- Radiation-Induced Xerostomia and Hyposalivation
- Seasonal Influenza
Route of Administration
- Intraductal Route
- Intramuscular Route
- Intratumoral Route
- Intravenous Route
Geographical Regions
- North America
- US
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- Singapore
Next Generation RNA Therapeutics Market: Key Segments
Which Modality Holds the Biggest Market Share for RNA Therapeutics?The market for next-generation RNA treatments is segmented across various modalities, including vaccines and therapeutics. According to the next generation RNA therapeutics market forecast, the therapeutics sub-segment is expected to hold a larger proportion (>80%) in 2035. Furthermore, during the forecast period, this sub-segment is anticipated to increase at a notable rate. This is mainly because medicines have a wider range of possible applications than vaccinations. Therapeutics can treat both acute and chronic illnesses, increasing their market potential, in contrast to vaccines, which are mostly preventive and target infectious diseases.
Which molecule type exhibits the fastest growth in the next-generation RNA therapeutics sector?
According to the industry prediction, saRNA molecules are expected to have around 60% of the total market share by 2035. Additionally, the market is anticipated to see a significant rise in the proportion of saRNA molecules, expanding at a CAGR of 73.6% over the course of the projected period. This is because, in contrast to other RNA therapies like siRNAs, its double-stranded structure allows for enhanced gene expression at the transcriptional level. This guarantees the development of larger amounts of proteins that can be used to treat illnesses.
Which Target Indication Has the Biggest Market Share for RNA Therapeutics?
The advanced solid tumors subsegment is anticipated to hold the largest (~35%) market share in 2035, according to the next generation RNA therapies market analysis. This trend can be attributed to the rising global prevalence of oncological diseases, which continue to pose significant health challenges. Furthermore, the hereditary bone marrow failure syndrome sub-segment is anticipated to register a comparatively higher CAGR in the near term. This growth is driven by the rarity and predominantly monogenic nature of inherited bone marrow failure disorders, coupled with the current lack of effective therapeutic options.
North America: Taking the Lead in the Market with the Highest Share
North America is expected to have the largest market share (more than 65%) for next-generation RNA therapies. This is due to significant public funding in RNA biology, which has driven increased clinical activity within the field.Next Generation RNA Therapeutics Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation RNA therapeutics market, focusing on key market segments, including [A] type of modality, [B] type of molecule, [C] therapeutic areas, [D] route of administration [E] and [F] key geographical regions.
- Market Landscape: A comprehensive evaluation of next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of modality, [B] type of molecule, [C] type of delivery vehicle, [D] phase of development [E] therapeutic area and [F] key niche market segments (circRNA and saRNA). Additionally, the chapter includes analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players (in terms of number of therapies).
- Technology Landscape: A comprehensive evaluation of technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, considering various parameters, such as [A] class of molecule, [B] type of molecule, [C] capabilities of the technology, [D] therapeutic area and [E] highest phase of development. Additionally, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their [F] year of establishment, [G] company size, [H] location of headquarters and [I] operational model.
- Drug Profiles: In-depth profiles of drug candidates that are in advanced stages of development, focusing on [A] details on its developer, [B] drug overview, [C] clinical trial information, [D] clinical trial endpoints, [E] clinical trial results and [F] estimated sales.
- Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various next generation RNA therapeutics and RNA vaccines, based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] type of sponsor, [F] therapeutic area, [G] study design, [H] leading organizations (in terms of number of trials), [I] focus area and [J] geography.
- Patent Analysis: Detailed analysis of various patents filed / granted related to next generation RNA therapeutics and RNA vaccines based on [A] type of patent (granted patents, patent applications and others), [B] patent publication year, [C] patent jurisdiction, [D] CPC symbols, [E] emerging focus areas, [F] patent age, [G] leading industry / non-industry players (in terms of number of patents filed / granted) and [H] patent valuation.
- Partnerships and Collaborations: An analysis of partnerships established in this sector based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] focus of partnership, [E] purpose of partnership, [F] therapeutic area, [G] most active players (in terms of number of partnerships) and [H] the regional distribution of partnership activity in this market.
- Funding and Investment Analysis: A detailed evaluation of the investments made in this domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] type of molecule, [D] amount invested, [E] geography, [F] purpose of funding, [G] stage of development, [H] therapeutic area, [I] most active players (in terms of number and amount of funding instances) and [J] leading investors (in terms of number of funding instances).
- Big Pharma Analysis: A comprehensive examination of various initiatives focused on next generation RNA therapeutics and RNA vaccines undertaken by major pharmaceutical companies based on several relevant parameters, such as [A] number of initiatives, [B] year of initiative, [C] type of initiative, [D] purpose of initiative, [E] focus of initiative and [F] location of headquarters.
Key Questions Answered in this Report
- Which are the leading companies in the next generation RNA therapeutics market?
- Which region dominates the next generation RNA therapeutics market?
- What are the key trends observed in the next generation RNA therapeutics market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by next generation RNA therapeutics developers?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
Additional Benefits
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. BACKGROUND
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
5. EXECUTIVE SUMMARY
6. INTRODUCTION
7. MARKET LANDSCAPE: RNA THERAPEUTICS AND RNA VACCINES
8. TECHNOLOGY LANDSCAPE
9. DRUG PROFILES
10. CLINICAL TRIAL ANALYSIS
11. PATENT ANALYSIS
12. PARTNERSHIPS AND COLLABORATIONS
13. FUNDING AND INVESTMENT ANALYSIS
14. BIG PHARMA INITIATIVES
15. GLOBAL NEXT GENERATION RNA THERAPEUTICS MARKET
16. NEXT GENERATION RNA THERAPEUTICS MARKET, BY TYPE OF MODALITY
17. NEXT GENERATION RNA THERAPEUTICS MARKET, BY TYPE OF MOLECULE
18. NEXT GENERATION RNA THERAPEUTICS MARKET, BY TARGET INDICATION
19. NEXT GENERATION RNA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
20. NEXT GENERATION RNA THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS
22. NEXT GENERATION RNA THERAPEUTICS MARKET, SALES FORECAST OF DRUGS
23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
24. MARKET OPPORTUNITY ANALYSIS: EUROPE
25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AlphaVax
- Arcturus Therapeutics
- BioNTech
- HDT Bio
- MiNA Therapeutics
- VLP Therapeutics
Methodology
LOADING...
